PMV Pharma is a clinical-stage precision oncology company developing small molecule drugs that target mutant p53 proteins in cancer patients. p53 is a tumor suppressor protein that normally eliminates cancer cells, but in roughly half of all cancers the p53 gene is mutated, causing the protein to misfold and lose its tumor-suppressing function. PMV Pharma's drugs are designed to physically correct the shape of specific mutant p53 proteins, restoring their cancer-killing function. PMV Pharma's lead and only clinical-stage candidate is rezatapopt, which targets the p53 Y220C mutation found in approximately 1% of all cancers. Rezatapopt is an oral, tumor-agnostic drug, meaning patients qualify based on their tumor's genetic mutation rather than where the tumor originated. Rezatapopt is currently in a pivotal Phase 2 trial called PYNNACLE; interim data across 103 patients showed a 34% overall response rate across all tumor types, and a 46% response rate in ovarian cancer. PMV Pharma plans to file an NDA for platinum-resistant ovarian cancer in Q1 2027. If approved, PMV Pharma plans to commercialize rezatapopt with its own focused sales force targeting oncologists who identify eligible patients via genomic sequencing. PMV Pharma has partnered with Foundation Medicine to develop a companion diagnostic. The company is pre-revenue and funds operations through equity raises. Longer term, PMV Pharma aims to expand rezatapopt's label to a broader tumor-agnostic indication and apply its p53 platform to other mutations beyond Y220C.